1.

Additional file 2 of Experienced disrespect & abuse during childbirth and associated birth characteristics: a cross-sectional survey in the Netherlands ...

1.

Additional file 3 of Experienced disrespect & abuse during childbirth and associated birth characteristics: a cross-sectional survey in the Netherlands ...

1.

Vitamin E but not 17β-estradiol protects against vascular toxicity induced by β-amyloid wild type and the dutch amyloid variant

2.

Vitamin E but not 17β-estradiol protects against vascular toxicity induced by β-amyloid wild type and the dutch amyloid variant

3.

Vitamin E but not 17β-estradiol protects against vascular toxicity induced by β-amyloid wild type and the dutch amyloid variant

4.

Vitamin E but not 17β-estradiol protects against vascular toxicity induced by β-amyloid wild type and the dutch amyloid variant

1.

Development and validation of the Basal and Squamous Cell Carcinoma Quality of Life (BaSQoL) Questionnaire

2.

Development and validation of the Basal and Squamous Cell Carcinoma Quality of Life (BaSQoL) Questionnaire

3.

Development and validation of the Basal and Squamous Cell Carcinoma Quality of Life (BaSQoL) Questionnaire

4.

Development and validation of the Basal and Squamous Cell Carcinoma Quality of Life (BaSQoL) Questionnaire

1.

Multi-Focal Splenic Tumour in a Belgian Patient and a Brief Review of the Literature on Littoral Cell Angioma

2.

Multi-Focal Splenic Tumour in a Belgian Patient and a Brief Review of the Literature on Littoral Cell Angioma

3.

Multi-Focal Splenic Tumour in a Belgian Patient and a Brief Review of the Literature on Littoral Cell Angioma

4.

Multi-Focal Splenic Tumour in a Belgian Patient and a Brief Review of the Literature on Littoral Cell Angioma

5.

Multi-Focal Splenic Tumour in a Belgian Patient and a Brief Review of the Literature on Littoral Cell Angioma

6.

Multi-Focal Splenic Tumour in a Belgian Patient and a Brief Review of the Literature on Littoral Cell Angioma

1.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

2.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

3.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

4.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

5.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

6.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

7.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

8.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

9.

A Belgian consensus protocol for autologous hematopoietic stem cell transplantation in multiple sclerosis.

1.

Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program.

2.

Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program.

3.

Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program.

4.

Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program.

5.

Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program.

6.

Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program.

7.

Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program.

8.

Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program.

9.

Real life safety and effectiveness of nivolumab in older patients with non-small cell lung cancer: Results from the Belgian compassionate use program.

1.

Recommendations for treatment in folliculotropic mycosis fungoides:Report of the Dutch Cutaneous Lymphoma Group

2.

Recommendations for treatment in folliculotropic mycosis fungoides:Report of the Dutch Cutaneous Lymphoma Group

3.

Recommendations for treatment in folliculotropic mycosis fungoides:Report of the Dutch Cutaneous Lymphoma Group

4.

Recommendations for treatment in folliculotropic mycosis fungoides:Report of the Dutch Cutaneous Lymphoma Group

1.

Quality assurance in postgraduate pathology training the Dutch way: regular assessment, monitoring of training programs but no end of training examination

1.

Immunohistochemistry as a screening tool for NTRK gene fusions: results of a first Belgian ring trial

2.

Immunohistochemistry as a screening tool for NTRK gene fusions: results of a first Belgian ring trial

3.

Immunohistochemistry as a screening tool for NTRK gene fusions: results of a first Belgian ring trial